D. Boral Capital Reaffirms “Buy” Rating for OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $20.00 price objective on the stock.

A number of other equities research analysts have also weighed in on OSTX. Lake Street Capital initiated coverage on OS Therapies in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $19.00 price objective on the stock. Maxim Group lifted their price objective on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $18.00.

OS Therapies Trading Down 1.2%

OSTX opened at $1.64 on Thursday. OS Therapies has a 12-month low of $1.12 and a 12-month high of $7.00. The stock has a 50-day moving average price of $1.63 and a 200-day moving average price of $2.37.

Insider Buying and Selling

In other OS Therapies news, major shareholder Shalom Auerbach sold 82,000 shares of OS Therapies stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $2.00, for a total value of $164,000.00. Following the sale, the insider now owns 2,664,199 shares of the company’s stock, valued at $5,328,398. The trade was a 2.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 13.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC raised its stake in OS Therapies Inc (NYSE:OSTX) by 120.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the period. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.